Lower Mortality Seen With Hemodiafiltration for Kidney Failure
WEDNESDAY, June 21, 2023 -- For patients with kidney failure, the use of high-dose hemodiafiltration results in a lower risk for death from any cause compared with high-flux hemodialysis, according to a study published online June 16 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2023 Category: Pharmaceuticals Source Type: news
Hemodiafiltration Reduced Dialysis Mortality in Kidney Failure
(MedPage Today) -- High-dose hemodiafiltration improved survival compared with standard hemodialysis for patients with kidney failure resulting in the need for kidney-replacement therapy, according to the randomized CONVINCE trial.
High-dose hemodiafiltration... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - June 17, 2023 Category: Urology & Nephrology Source Type: news
New Dialysis Technique Boosts Survival in Kidney Failure New Dialysis Technique Boosts Survival in Kidney Failure
High-dose hemodiafiltration led to substantially better survival of patients with end-stage kidney disease compared with conventional hemodialysis after a median 30 months in a large, prospective study.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 16, 2023 Category: Transplant Surgery Tags: Nephrology News Source Type: news
Continuous veno-venous hemodiafiltration in metformin-associated lactic acidosis caused by a suicide attempt: a report of two cases - Tuncali B, Temizkan K ırkayak AG, Zeyneloğlu P.
Lactic acidosis is the most important and life-threatening side effect of metformin that is widely used in the treatment of type 2 diabetes mellitus. In this case report, two cases who were treated in our intensive care unit for lactic acidosis due to high... (Source: SafetyLit)
Source: SafetyLit - September 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
The therapeutic effect of high-volume hemofiltration on sepsis: A systematic review and meta-analysis
Conclusion(s): The meta-analysis results suggested that treatment programs contained HVHF did not change the outcomes of patients with sepsis. So far, related studies on the use of HVHF in critically ill patients with sepsis or septic shock is rare. Researchers should consider additional large multicenter randomized controlled trials. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news
Rapid Fluid Removal May Up Mortality in Critically Ill With AKI
MONDAY, June 10, 2019 -- Among critically ill patients with acute kidney injury, use of higher net ultrafiltration (NUF) rates for continuous venovenous hemodiafiltration is associated with lower survival, according to a secondary analysis published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2019 Category: Pharmaceuticals Source Type: news
The Effect of Online Hemodiafiltration on Nutritional Status The Effect of Online Hemodiafiltration on Nutritional Status
What additional benefits might high-volume online hemodiafiltration offer over conventional hemodialysis?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Baxter shares dip despite Q2 earnings beat
Shares in Baxter (NYSE:BAX) have fallen slightly today despite the medical giant beating expectations on Wall Street with its second quarter earnings results.
The Deerfield, Ill.-based company posted profits of $343 million, or 63¢ per share, on sales of $2.8 billion for the three months ended June 30, seeing profits grow 29.4% while sales grew 9.1% compared with the same period last year.
Adjusted to exclude one-time items, earnings per share were 77¢, just ahead of the 71¢ expectations on Wall Street where analysts expected too see sales of $2.8 million, which the company met.
“Our solid second quarter performa...
Source: Mass Device - July 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Baxter Source Type: news
Baxter touts Theranova HDx dialysis tech study data
Baxter (NYSE:BAX) today released new data from studies exploring expanded hemodialysis with its Theranova dialyzer, touting the device’s ability to clear large middle molecules at a higher rate than standard hemodialysis and equal or faster removal rates compared to high-volume hemodiafiltration.
Results from a number of studies and poster presentations on the Theranova dialyzer were presented at the 55th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this month, Baxter said.
The Deerfield, Ill.-based company’s Theranova dialyzer is designed to extend the range...
Source: Mass Device - May 31, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Dialysis Baxter Source Type: news
Mortality in Patients on Hemodiafiltration vs Hemodialysis Mortality in Patients on Hemodiafiltration vs Hemodialysis
Might hemodiafiltration patients realize better outcomes than those receiving hemodialysis?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Baxter touts minimal albumin loss in Theranova HDx therapy studies
Baxter (NYSE:BAX) today released data from a study of expanded hemodialysis using its Theranova dialyzer, touting that the device was shown to successfully remove mid-sized uremic toxins from the body with minimal albumin loss.
Results from the study were presented at the American Society of Nephrology’s annual Kidney Week Congress, the company said.
The Deerfield, Ill.-based company’s Theranova dialyzer is designed to extend the range of molecules that it filters from the blood, which the company claims “more closely mimics the natural kidney.” The expanded hemodialysis therapy works on standard e...
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Baxter Source Type: news
Baxter launches 2 studies of HDx hemodialysis using Theranova dialyzer
Baxter (NYSE:BAX) said today it launched 2 new clinical trials exploring expanded HDx hemodialysis therapy using its Theranova dialyzer.
The Deerfield, Ill.-based company’s HDx therapy uses a Theranova dialyzer designed to extend the range of molecules that it filters from the blood, claiming it “more closely mimics the natural kidney.” The therapy works on standard equipment and does not require the generation of replacement fluid, Baxter said.
“Millions of patients with chronic kidney disease rely on renal innovations every day, many of whom have ESRD and require HD therapy to stay alive. HDx therapy...
Source: Mass Device - October 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Baxter Source Type: news
A New RCT Looks at Online Hemodiafiltration A New RCT Looks at Online Hemodiafiltration
Dr Desai describes a rare phenomenon in the current field of nephrology: an RCT.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 6, 2017 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
Baxter touts Sharesource in-home peritoneal dialysis patient monitoring study data
Baxter (NYSE:BAX) today released data from multiple studies of its Sharesource remote patient monitoring technology used for peritoneal dialysis patient care.
Data from the study was presented at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this week.
Sharesource is a 2-way cloud-based technology offered with the company’s Homechoice Claria automated PD system to allow providers to connect with patients using the device and verify patient adherence, the company said.
Data from the 1st study study, which included 399 APD patients using remote patient man...
Source: Mass Device - June 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Patient Monitoring Baxter Source Type: news
Baxter touts HDx Theranova data for ‘ extended ’ hemodialysis
Baxter (NYSE:BAX) today released data from 2 independent studies of its novel HDx therapy using the Theranova dialyzer, touting the effective removal of small and mid-sized toxins at similar rates compared to hemodiafiltration.
Results from the trial were presented at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association this week, the company said.
The Deerfield, Ill.-based company’s HDx therapy uses a Theranova dialyzer designed to extend the range of molecules that it filters from the blood, claiming it “more closely mimics the natural kidney,” according ...
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Baxter Source Type: news
